Abstracts heparin (UFH) in many patients to achieve greater clinical efficacy and pharmacoeconomic efficiency. Most hospitals have not achieved clinically effective use of LMWH and UFH in the treatment and prevention of thrombotic disorders. The Clinical Effectiveness Initiative (CEI) was designed to help hospitals achieve better data assessment to measure patient outcomes, reduce medical errors, reduce risk, and reach towards optimal financial performance in these patient groups. METHODS: CEI begins with analysis of data available from the UB-92 and pharmacy or cost-accounting systems. The actuarial analysis provides a risk-adjusted comparison of patient cohorts receiving antithrombotics (LMWH or UFH). Results are reported to the institution in a format suitable for use with performance improvement activities and physicians. The total cost for each cohort is broken down into drug acquisition costs and costs associated with laboratory tests, level of care, supplies and length of stay. RESULTS: Results completed from two hospitals in 87 DRGs that had at least 10 discharges in each drug category (5374 LMWH, 9380 UFH) showed a case mix adjusted average savings of $698 per discharge. The study to-date has showed that the use of LMWH reduced overall cost in many high-use categories, despite the higher drug acquisition cost. Those included DVT, Hip and Knee replacement cases. Findings also demonstrated an opportunity for substantial savings with greater selective use of LMWH in several cohorts that will shared in chart form. The data analysis and structured interviews with hospital leadership presented valuable insights into how best to facilitate changes in practice patterns that can be continually measured. CONCLUSIONS: We conclude that the data assessment and efficiency modeling capabilities of CEI are powerful tools to help hospitals achieve clinical effectiveness, especially when integrated into a hospital's performance improvement program.
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DEVELOPING A HEALTH ECONOMIC EVALUATION DATABASE IN JAPAN:
JEED PROJECT Fukuda T, Tsutani K, Kobayashi Y University of Tokyo, Bunkyo, Tokyo, Japan OBJECTIVES: The Japan Economic Evaluation Database (JEED) project aims for critical appraisal of health economic evaluation studies in Japan and build a database with structured abstracts in collaboration with NHS-EED. With careful preparation in 2001, we performed handsearching of all the scientific articles and reports in the health economic fields in Japan in 2002. We analyzed current status of economic evaluation studies and methodological issues. METHODS: Since January 2002, we started to hand-search all articles and reports pub-lished in Japanese journals. Key words for handsearching were types of economic evaluations such as costeffectiveness analysis or cost-utility analysis and methodological terms such as utility score, willingness to pay, QOL measurement and costing. We also adopted words for study areas such as health economic evaluations and pharmacoeconomics. We classified the articles into some categories and picked up methodological issues in Japan. RESULTS: Up to the end of September 2002, we identified 223 articles and reports related to health economic evaluations that appeared in a total of 4881 journals. Most of the articles were general remarks or proceedings. Thirty-four articles out of 233 were classified as original articles, only 6 of which could be identified as full economic evaluations. Nineteen articles were on costing and 4 were on measuring effectiveness or utility. We picked up some issues in economic evaluation studies in Japan. Most of the studies used reimbursement fee though there were some studies for actual costing. Because QOL data for health status were limited in Japanese population, many studies adopted data from foreign countries. There were some articles which did not use terms for economic evaluation studies correctly. CONCLUSIONS: To promote good economic evaluation studies in Japan, systematic critical appraisals and dissemination of information of good studies are needed. We may have to consider methodological guidelines or recommendations for good economic evaluation studies.
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DO DIFFERENCES AMONG COST-EFFECTIVENESS ANALYSIS GUIDELINE RECOMMENDATIONS AFFECT POLICY CONCLUSIONS?
Schackman BR 1 , Gold HT 1 , Stone PW 2 , Neumann PJ 3 1 Weill Medical College of Cornell University, New York, NY, USA; 2 Columbia University School of Nursing, New York, NY, USA; 3 Harvard University, Boston, MA, USA OBJECTIVES: Guidelines for conducting cost-utility analyses (CUAs) contain inconsistent recommendations for selecting cost, quality of life, and discount rate parameters. Sensitivity analyses can indicate whether adhering to different guidelines results in different policy recommendations. The purpose of this study is to investigate the use of sensitivity analyses to test economic parameters in the cost-utility literature. METHODS: Recommendations from published guidelines are summarized. CUAs of pharmaceutical therapies identified in a prior study (N = 71 articles) were reviewed and further audited. We identified threshold CU ratios (N = 36) and base cases for which sensitivity analyses were reported (N = 123). For each base case, up to 2 sensitivity analyses for cost (N = 97), quality of life (N = 136), and discount rate (N = 127) were examined. RESULTS: There are substantial disagreements among the guidelines regarding economic parameters. The most frequently mentioned threshold CU ratios were $20,000/QALY, $50,000/
